Thalidomide: From Villain to Cancer Fighter
also underway against melanoma, myelodysplastic syndromes, glioma, prostate, lymphoma and other solid tumors. 2
References
1. Bartlett, J. et. al. The evolution of thalidomide and its ImiD derivatives as anticancer agents. Nature Reviews Cancer, Vol. 4, No. 4, pp. 314-322 (April 2004)
2. Bartlett, J. et. al. Phase I study to determine the safety, tolerability, and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastic malignant melanoma and other advanced cancers. Brit. J. Cancer, Vol. 90, pp. 955-961 (2004) 3. Coussens, L. and Werb, Z. Inflammation and Cancer. Nature, Vol. 420, No. 6917, pp. 860-7 (Dec. 19-26, 2002) 4. Singhal, S. Antitumor activity of thalidomide in refractory multiple myeloma. New Eng. J. Med., Vol.341, No. 21, pp. 1565-1571 (1999)
Latest Articles